Register entry
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 21
- Countries
- 0
Exclusivity
Patents and exclusivities
21| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8511304 | ANORO ELLIPTAumeclidinium bromide; vilanterol trifenatate | product | Jun 2027 |
| 8511304*PED | ANORO ELLIPTAumeclidinium bromide; vilanterol trifenatate | use | Dec 2027 |
| 7488827 | ANORO ELLIPTA, TRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatate; umeclidinium bromide; vilanterol trifenatate | substance, product | Dec 2027 |
| 8534281 | TRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatate | product | Mar 2030 |
| 8534281*PED | TRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatate | use | Sept 2030 |
| 8746242 | TRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatate | product | Oct 2030 |
| 11090294 | ANORO ELLIPTA, TRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatate; umeclidinium bromide; vilanterol trifenatate | use | Nov 2030 |
| 12396986 | ANORO ELLIPTA, TRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatate; umeclidinium bromide; vilanterol trifenatate | product | Nov 2030 |
| 9750726 | ANORO ELLIPTA, TRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatate; umeclidinium bromide; vilanterol trifenatate | product | Nov 2030 |
| 8746242*PED | TRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatate | use | Apr 2031 |
Enquiry
Common questions
- Is GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND FDA approved?
- GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.